Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 63 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04279379Phase 2
- Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced MalignanciesCompletedNCT04278859Phase 1
- The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryTerminatedNCT04277663Phase 3
- Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedNCT04276376Phase 2
- Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II MelanomaCompletedNCT04274816Phase 1
- Study on TSR-042 in Advanced Clear Cell SarcomaTerminatedNCT04274023Phase 2
- Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerWithdrawnNCT04272645Phase 2
- Intratumoral Microdosing of Motolimod in HNSCCTerminatedNCT04272333Early Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
- Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)CompletedNCT04271813Phase 2
- Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerCompletedNCT04271384Phase 2
- Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedNCT04270864Phase 1
- Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric CancerActive, not recruitingNCT04267549Phase 2
- A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung CancerWithdrawnNCT04267237Phase 2
- Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade GliomaCompletedNCT04267146Phase 1/2
- Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1
- A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial CancerStatus unknownNCT04264936Phase 1/2
- Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionStatus unknownNCT04263870Phase 2
- Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedNCT04263090Phase 1/2
- Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerCompletedNCT04263051Phase 2
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedNCT04262856Phase 2
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingNCT04262466Phase 1/2
- The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell CarcinomaStatus unknownNCT04262427Phase 1/2
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
- A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONWithdrawnNCT04262375Phase 2
- Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility StudyCompletedNCT04262089Phase 1
- A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
- Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCCompletedNCT04260126Phase 2
- A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTEWithdrawnNCT04258683Phase 2
- Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerStatus unknownNCT04258644Phase 2
- Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2
- IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal CancerTerminatedNCT04258111Phase 2
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedNCT04257448Phase 1/2
- COL Immunotherapy Before Radiochimio + IpilimumabCompletedNCT04256213Not applicable
- Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04255836Phase 2
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung CancerStatus unknownNCT04252365Phase 2
- Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric CancerActive, not recruitingNCT04250948Phase 2
- A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2
- An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT04250155Phase 1
- Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 PositiveActive, not recruitingNCT04249739Phase 2
- Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerWithdrawnNCT04249167Early Phase 1
- Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type MelanomaStatus unknownNCT04248387Phase 2
- Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.CompletedNCT04247165Phase 1/2
- Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04245514Phase 2
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)Active, not recruitingNCT04241185Phase 3
- Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerStatus unknownNCT04239443Phase 2
- Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin LymphomaStatus unknownNCT04239170Phase 2
- GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1
- Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical CancerStatus unknownNCT04238988Phase 2
- Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)Active, not recruitingNCT04238637Phase 2
- A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological CancerStatus unknownNCT04236362Phase 1/2
- A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
- P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaStatus unknownNCT04233840Phase 1/2
- Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2
- Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal CancerStatus unknownNCT04231552Phase 1/2
- Pembrolizumab in Early Stage Colon CancerWithdrawnNCT04231526Phase 2
- Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell LymphomaStatus unknownNCT04231370Phase 2
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
- Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study GroupActive, not recruitingNCT04230759Phase 2
- Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersCompletedNCT04230408Phase 2
- Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaWithdrawnNCT04230330Phase 1
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRCStatus unknownNCT04229537Phase 1
- Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.Active, not recruitingNCT04229459Phase 2
- Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT04227509Phase 2
- Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT04225364Phase 2
- Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile CancerCompletedNCT04224740Phase 2
- Longitudinal Immune-phenotyping of HCC Following MK-3475Active, not recruitingNCT04224480Phase 1
- Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid CarcinomaCompletedNCT04224337Phase 2
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1CompletedNCT04223804Phase 1
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
- Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT04221555Phase 2
- Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideCompletedNCT04221529Phase 2
- Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.Active, not recruitingNCT04220944Phase 1
- A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT04220307Phase 2
- MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT04216953Phase 1/2
- A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3
- SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerStatus unknownNCT04213898Phase 1/2
- Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1
- Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
- The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal CancerCompletedNCT04212598Phase 2
- Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.TerminatedNCT04212026Phase 2
- Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
- Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
- Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical LesionsStatus unknownNCT04211103Phase 2
- Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
- A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial CarcinomaStatus unknownNCT04211012Phase 2
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Phase 3
- Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
- A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsStatus unknownNCT04207463Phase 2
- A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
- Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsCompletedNCT04205552Phase 2
- A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest CancerStatus unknownNCT04203719Phase 2
- INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)WithdrawnNCT04203511Phase 3
- Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
- Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal CancerStatus unknownNCT04202978Phase 1/2
- Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)CompletedNCT04202653Phase 2